Skip to main content

Table 4 Validation of involved pathways by in silico / in patient analyses

From: TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness

Pathway name and status in A375 vs SK-Mel-28

GEO Analysis (Affymetrix)

biopsy of melanomas (n = 45)

biopsy of nevi (n = 18)

t test (melanomas vs nevi)

TIMP3 (Down-regulated, Illumina)

81.64 ± 9.1

92.56 ± 7.23

p value 0.00006

IL1RA (Down-regulated, Luminex)

60.02 ± 13.34

73.89 ± 12.15

p value 0.00029

VEGFA (Up-regulated, Luminex)

79.31 ± 12.39

60.78 ± 18.15

p value 0.00132

  1. Cytokines found significantly modulated in this study by transcriptomics, proteomics and/or secretome analyses comparing A375 vs SK-MEL-28 cells have been matched with transcriptomics analyses from patients biopsies (45 melanomas vs 18 nevi). In this Table the consensus is reported